乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Oncology/Hematology >

Myeloma

News, opinions and meeting coverage in oncology/hematology.

A vial of Xgeva over a microscope image of multiple myeloma

<乌鸦传媒>Denosumab Use in Myeloma Soars for No Obvious Reason

More expensive than competitor without being better, so why does it now have nearly half the market?

MGUS with the letters filled with a microscope image of multiple myeloma

<乌鸦传媒>Serum Immune Markers May Predict Conversion From MGUS to Myeloma

Results could support annual blood tests and risk assessment for those with MGUS and its subtype, light-chain MGUS

<乌鸦传媒>Combination Regimen Extends PFS in Myeloma

Large benefit but relevance of comparator questioned

<乌鸦传媒>NCCN Refines MM Treatment Guidelines

'An attempt to help the clinician make better decisions,' expert says

<乌鸦传媒>Longer PFS in Myeloma with Add-On Daratumumab

Anti-CD38 drug boosts response to VMP regimen

<乌鸦传媒>CAR T Cells Drive Outcomes in MM

Studies show promise for precision immunotherapy

<乌鸦传媒>Novel Agent Shows Antitumor Activity in TRK-Fusion Cancers

Tumor genetics define treatment approach in early-stage trials

<乌鸦传媒>MSK Cancer Alliance: Mainly About Medicine

Bi-directional relationship strengthens regional cancer care

<乌鸦传媒>Pembrolizumab Plus Lenalidomide Gets Response in MM

Combo shows signs of benefit in relapsed/refractory myeloma

<乌鸦传媒>Novel Agent Promising in Pretreated Myeloma

Phase II trial shows 18-month median survival with isatuximab

<乌鸦传媒>Plitidepsin Shows Activity in Multiple Myeloma

Early data favorable for sea squirt drug

<乌鸦传媒>Combo Boosts PFS in Tough-to-Treat Myeloma

Recurrent or relapsed disease susceptible to daratumumab-bortezomib-dexamethasone

<乌鸦传媒>Revlimid Maintenance Benefits Multiple Myeloma

Prolonged overall survival in patients post-autologous stem cell transplant

<乌鸦传媒>Transplant Remains King for New Myeloma

Significant improvement in PFS versus systemic treatment

<乌鸦传媒>One Proteasome Inhibitor Tops Another in Relapsed Myeloma

Progression-free survival doubled with carfilzomib versus bortezomib

<乌鸦传媒>PFS Rises in Progressive Myeloma with Targeted Biologic

Adding elotuzumab boosts median progression-free survival by almost 5 months.

<乌鸦传媒>Part 2: Oncologists Weigh In on PBS Cancer Documentary

Six specialists share their impressions of Ken Burns' cancer opus.

<乌鸦传媒>HDAC Inhibitor OK'd for Multiple Myeloma

Panobinostat targets histone deacetylases; first of its kind to win approval in myeloma.

<乌鸦传媒>ASCO: Myeloma Study Results Inconclusive

CHICAGO -- A trial comparing two immunomodulatory regimens for myeloma failed to demonstrate noninferiority for the newer drug.

<乌鸦传媒>ASCO: Combo Extends PFS in Relapsed Myeloma

CHICAGO -- Progression-free survival in relapsed/refractory myeloma increased significantly in patients treated with a three-drug regimen that included panobinostat versus a two-drug regimen, a randomized trial showed.

<乌鸦传媒>OncoBriefs: Myeloma Tx, In Situ Melanoma

Superficial melanoma conferred a risk of recurrent invasive melanoma similar to that of primary invasive melanoma, Australian investigators reported. The study is one of several oncology-related news items summarized in OncoBriefs.

<乌鸦传媒>Infection High in Myeloma, with High Mortality

ATLANTA -- More than a fifth of patients with multiple myeloma died of infection within a year of diagnosis, Swedish investigators reported here.

<乌鸦传媒>Oral Azacitidine Safe, Effective in Low-Risk MDS

ATLANTA -- Oral azacitidine (Vidaza) given for up to 21 days per 4-week cycle for myelodysplastic syndrome appeared safe and effective in patients with lower-risk disease, a researcher said here.

<乌鸦传媒>FDA: Revlimid Linked to Second Cancers

Treatment of multiple myeloma with lenalidomide (Revlimid) as maintenance therapy is associated with an increased risk of second primary cancers, the FDA warned.

<乌鸦传媒>Clinical Notes: Beware the Seat Heater

乌鸦传媒 debuts a new regular feature, a roundup of clinical news you might otherwise have missed. This week we led with a report that heated car seats can leave passengers with "toasted skin syndrome."

<乌鸦传媒>Withdrawal Tough With Novel Drug for Myelofibrosis

The novel Janus kinase (JAK) inhibitor ruxolitinib relieves myelofibrosis symptoms, but withdrawal from the drug can be severe, researchers warned.

<乌鸦传媒>Medicare to Cover More PET Scans for Cancer Diagnosis

BALTIMORE -- The Centers for Medicare and Medicaid Services announced expanded coverage of PET scans for Medicare patients suspected of having most cancers.